- Novartis assembles 2nd molecular glue deal with Monte Rosa, this one worth up to $5.7B Fierce Biotech
- Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases GlobeNewswire
- Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics Yahoo Finance
- Updated: Novartis extends deal spree with $120M for Monte Rosa’s immune degraders Endpoints News
- Novartis dives deeper into protein degraders with second Monte Rosa deal BioPharma Dive
Source link
